The Role of Resistance Training in Non Alcoholic Fatty Liver Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01264198

Enrollment

Registered

2010-12-21

Start date

2010-12-31

Completion date

2012-10-31

Last updated

2014-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD (Non-Alcoholic Fatty Liver Disease), Resistance Training

Brief summary

The aim of the study is to evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD.

Detailed description

Background: Non Alcoholic Fatty Liver Disease (NAFLD) is the most prevalent liver disease in developed countries with a prevalence rate of 20-30 % of adults. About 10-25% of these individuals are estimated to meet the current diagnostic criteria for Non Alcoholic Steatohepatitis (NASH) and some may progress to Cirrhosis and liver failure. NAFLD is now recognized as the hepatic manifestation of the metabolic syndrome. Recent data shows that NAFLD might also predict the tendency to develop diabetes mellitus and coronary artery disease. The drug of choice for NAFLD is yet to be found. The recommended treatment of NAFLD includes weight reduction and Physical Activity (PA), but the data of the effect of Resistance Training (RT) PA on NAFLD is scant. Aim of the study: To evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD. Study design: Randomized Clinical Trial. Patients will be randomly allocated to 2 arms (intervention and control). The intervention arm will perform RT, whereas control arm will be advised to perform home stretching. Medical examination will be performed at week 0 (baseline) and at week 13 using uniform protocols.

Interventions

BEHAVIORALResistance Training

Supervised Resistance Training

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Ultrasound diagnosed fatty liver.

Exclusion criteria

* Presence of HBsAg or anti-HCV antibodies (will be obtained from blood tests at the liver clinic). * Patients with known diabetes treated with antidiabetic medications. * Patients with known kidney disease, CHD, lung disease, inflammatory bowel disease. * Excessive alcohol consumption ≥ 30 g/day in men or 20 g/ day in women.

Design outcomes

Primary

Measure	Time frame
The HRI value will be reduced in the intervention arm as compared to the The The change in Hepato-Renal Index (HRI) evaluated by ultrasound (US).	week 0 and week 13

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026